Literature DB >> 29477394

A Health Economics Approach to US Value Assessment Frameworks-Summary and Recommendations of the ISPOR Special Task Force Report [7].

Louis P Garrison1, Peter J Neumann2, Richard J Willke3, Anirban Basu4, Patricia M Danzon5, Jalpa A Doshi6, Michael F Drummond7, Darius N Lakdawalla8, Mark V Pauly5, Charles E Phelps9, Scott D Ramsey10, Adrian Towse11, Milton C Weinstein12.   

Abstract

This summary section first lists key points from each of the six sections of the report, followed by six key recommendations. The Special Task Force chose to take a health economics approach to the question of whether a health plan should cover and reimburse a specific technology, beginning with the view that the conventional cost-per-quality-adjusted life-year metric has both strengths as a starting point and recognized limitations. This report calls for the development of a more comprehensive economic evaluation that could include novel elements of value (e.g., insurance value and equity) as part of either an "augmented" cost-effectiveness analysis or a multicriteria decision analysis. Given an aggregation of elements to a measure of value, consistent use of a cost-effectiveness threshold can help ensure the maximization of health gain and well-being for a given budget. These decisions can benefit from the use of deliberative processes. The six recommendations are to: 1) be explicit about decision context and perspective in value assessment frameworks; 2) base health plan coverage and reimbursement decisions on an evaluation of the incremental costs and benefits of health care technologies as is provided by cost-effectiveness analysis; 3) develop value thresholds to serve as one important input to help guide coverage and reimbursement decisions; 4) manage budget constraints and affordability on the basis of cost-effectiveness principles; 5) test and consider using structured deliberative processes for health plan coverage and reimbursement decisions; and 6) explore and test novel elements of benefit to improve value measures that reflect the perspectives of both plan members and patients.
Copyright © 2018 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  augmented cost-effectiveness analysis; benefit-cost analysis; multi-criteria decision analysis; value frameworks

Mesh:

Year:  2018        PMID: 29477394     DOI: 10.1016/j.jval.2017.12.009

Source DB:  PubMed          Journal:  Value Health        ISSN: 1098-3015            Impact factor:   5.725


  23 in total

1.  Cost-Effectiveness of Biological Asthma Treatments: A Systematic Review and Recommendations for Future Economic Evaluations.

Authors:  R Brett McQueen; Danielle N Sheehan; Melanie D Whittington; Job F M van Boven; Jonathan D Campbell
Journal:  Pharmacoeconomics       Date:  2018-08       Impact factor: 4.981

2.  Prioritization and Refinement of Patient-Informed Value Elements as Attributes for Chronic Obstructive Pulmonary Disease Treatment Preferences.

Authors:  Julia F Slejko; Yoon Duk Hong; Jamie L Sullivan; Robert M Reed; Susan dosReis
Journal:  Patient       Date:  2021-02-08       Impact factor: 3.883

3.  Analysis of Stakeholder Engagement in the Public Comments of ICER Draft Evidence Reports.

Authors:  Jean A Gerlach; Brian Snow; Katherine M Prioli; Ronald Vertsman; Julie Patterson; Laura T Pizzi
Journal:  Am Health Drug Benefits       Date:  2020-09

4.  SF-6D utility scores for alcohol use disorder status and alcohol consumption risk levels in the US population.

Authors:  Carolina Barbosa; Jeremy W Bray; William N Dowd; Alan Barnosky; Eve Wittenberg
Journal:  Addiction       Date:  2020-08-27       Impact factor: 6.526

Review 5.  How to Value Orphan Drugs? A Review of European Value Assessment Frameworks.

Authors:  Alessandra Blonda; Yvonne Denier; Isabelle Huys; Steven Simoens
Journal:  Front Pharmacol       Date:  2021-05-12       Impact factor: 5.810

6.  The promise of Immuno-oncology: implications for defining the value of cancer treatment.

Authors:  Howard L Kaufman; Michael B Atkins; Prasun Subedi; James Wu; James Chambers; T Joseph Mattingly; Jonathan D Campbell; Jeff Allen; Andrea E Ferris; Richard L Schilsky; Daniel Danielson; J Leonard Lichtenfeld; Linda House; Wendy K D Selig
Journal:  J Immunother Cancer       Date:  2019-05-17       Impact factor: 13.751

7.  Challenges in assessing the clinical utility and economic value of immune checkpoint inhibitor therapies of Cancer.

Authors:  Peter Paul Yu; Omar Eton; Louis P Garrison
Journal:  J Immunother Cancer       Date:  2019-09-03       Impact factor: 13.751

8.  The Impact of Brexit on Pharmaceuticals and HTA.

Authors:  Paula K Lorgelly
Journal:  Pharmacoecon Open       Date:  2018-06

Review 9.  Value-Based Reimbursement in Collectively Financed Healthcare Requires Monitoring of Socioeconomic Patient Data to Maintain Equality in Service Provision.

Authors:  Toomas Timpka; James M Nyce; Isis Amer-Wåhlin
Journal:  J Gen Intern Med       Date:  2018-09-11       Impact factor: 6.473

Review 10.  Economic Evaluation for Health Investments En Route to Universal Health Coverage: Cost-Benefit Analysis or Cost-Effectiveness Analysis?

Authors:  Anthony J Culyer; Kalipso Chalkidou
Journal:  Value Health       Date:  2018-07-26       Impact factor: 5.725

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.